7QD Stock Overview
Clover Health Investments, Corp. provides medicare advantage plans in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Clover Health Investments, Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.63 |
| 52 Week High | US$1.45 |
| 52 Week Low | US$0.57 |
| Beta | 1.85 |
| 1 Month Change | -13.22% |
| 3 Month Change | -29.87% |
| 1 Year Change | -5.51% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -93.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7QD | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 4.8% | 0.6% | 1.1% |
| 1Y | -5.5% | -1.8% | 1.9% |
Return vs Industry: 7QD underperformed the German Healthcare industry which returned -3.9% over the past year.
Return vs Market: 7QD underperformed the German Market which returned 2% over the past year.
Price Volatility
| 7QD volatility | |
|---|---|
| 7QD Average Weekly Movement | 7.0% |
| Healthcare Industry Average Movement | 6.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 7QD's share price has been volatile over the past 3 months.
Volatility Over Time: 7QD's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 552 | Andrew Toy | www.cloverhealth.com/en/ |
Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.
Clover Health Investments, Corp. Fundamentals Summary
| 7QD fundamental statistics | |
|---|---|
| Market cap | €314.45m |
| Earnings (TTM) | -€199.00m |
| Revenue (TTM) | €1.90b |
0.2x
P/S Ratio-1.6x
P/E RatioIs 7QD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7QD income statement (TTM) | |
|---|---|
| Revenue | US$2.04b |
| Cost of Revenue | US$1.78b |
| Gross Profit | US$259.85m |
| Other Expenses | US$473.21m |
| Earnings | -US$213.36m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | -0.43 |
| Gross Margin | 12.76% |
| Net Profit Margin | -10.48% |
| Debt/Equity Ratio | 0% |
How did 7QD perform over the long term?
See historical performance and comparison